The companies will explore a next-generation drug innovation model by linking AI-enabled discovery with automation-driven development, manufacturing, and quality execution.
The agreement gives Formycon access to integrated drug substance and drug product manufacturing from OneSource’s biologics facility in Bangalore, India.
The kit provides standardized Chinese hamster ovary cells, reagents, and protocols intended to reduce troubleshooting during transient protein expression.
